Pharma Report 2012: Get Back in Shape

Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

4    Novartis    $19.2B    up 6.7%

Global revenue:  $58.5B (3rd); up 15.6%

R&D spend: $9.2B (1st), up 13.6%; 15.7% of rev.

Top brands: Diovan/Co-Diovan ($2.3B); Gleevec ($1.5B); Zometa ($642M); Sandostatin ($574M)

Planned launches: Bexsero (men. B vacc.); Seebri Breezhaler (NVA237)/QVA149 (COPD)

Promotional spend: $973M (6th); 5.1% of rev.

Patent expirations: Diovan (2012); Zometa (2013); Gleevec (2015)

Novartis is bracing for some ugly patent exclusivity losses, with ­blockbuster Femara having gone off patent and $2.3-billion Diovan, the company's top seller, facing generic competition in September. Next year, $642-million Zometa goes over the patent cliff, and in 2015, $1.5-billion Gleevec loses exclusivity. But the Swiss giant has cobbled together an Alpine portfolio from steadily-performing smaller brands while diversifying its business into generics (Sandoz), vaccines and diagnostics and, most recently, vision care with its acquisition of Alcon in 2010. The company boasts a muscular R&D operation, as evidenced by MS drug Gilenya, a likely blockbuster approved in 2010, and Arcapta Neohaler for COPD, approved in July, along with a robust late-stage pipeline. However, Novartis has been plagued by manufacturing issues at plants in Quebec and Nebraska. Other potential pitfalls include safety concerns about Gilenya that could hamper that key product's potential, and FDA delays on approvals of the Menveo vaccine and Seebri Breez­haler (NVA237).

Back to first page

Page 4 of 21
You must be a registered member of MMM to post a comment.

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters